Skip to main content

Table 1 Exploratory endpoints of this study

From: Comparative study of the inhibitory effect on bone erosion progression with denosumab treatment and conventional treatment in rheumatoid arthritis patients: study protocol for an open-label randomized controlled trial by HR-pQCT

1) HR-pOCT measurements

(1) Measurements in the second and third metacarpal bones and in the wrist joint

• Changes from baseline in periarticular BMD

• Changes from baseline in periarticular bone micro-architecture

• Changes from baseline in the width of joint space

• Changes from baseline in BMD at the rim of erosive lesions

(2) Measurements in the tibial bone

• Changes from baseline in BMD

• Changes from baseline in bone micro-architecture

2) Magnetic resonance imaging measurements

• Changes from baseline in the extent of osteitis

• Changes from baseline in the extent of bone erosion

• Changes from baseline in synovitis score

3) Musculoskeletal ultrasound measurements

• Changes from baseline in synovitis score

• Changes from baseline in the extent of bone erosion

4) X-ray measurements

• Changes from baseline in bone erosion score

• Changes from baseline in joint space narrowing score

• Changes from baseline in the modified total Sharp score

5) DXA measurements

• Changes from baseline in lumbar spine BMD

• Changes from baseline in femoral BMD

6) Changes from baseline in bone/cartilage turnover markers

7) Changes from baseline in other biomarkers

8) Changes from baseline in DAS28

  1. Abbreviations: BMD bone mineral density, DAS28 disease activity score in 28 joints, DXA dual-energy x-ray absorptiometry, HR-pQCT high-resolution peripheral quantitative computed tomography.